Electrospray ionization mass spectrometry (ESI MS) is a powerful investigative tool to analyze the reactions of metallodrugs with proteins and peptides and characterize the resulting adducts. Here, we have applied this type of approach to four experimental anticancer gold(III) compounds for which extensive biological and mechanistic data had previously been gathered, namely, Auoxo6, Au2phen, AUL12, and Aubipyc. These gold(III) compounds were reacted with two representative proteins, i.e., human serum albumin (HSA) and human carbonic anhydrase I (hCA I), and with the C-terminal dodecapeptide of thioredoxin reductase. ESI MS analysis allowed us to elucidate the nature of the resulting metal–protein adducts from which the main features of the occurring metallodrug–protein reactions can be inferred. In selected cases, MS data were integrated and supported by independent 1H NMR and UV–Vis absorption measurements to gain an overall description of the occurring processes. From data analysis, it emerges that most of the investigated gold(III) complexes, endowed with an appreciable oxidizing character, undergo quite facile reduction to gold(I); the resulting gold(I) species tightly associate with the above proteins/peptides with a remarkable selectivity for free cysteine residues. In contrast, in the case of the less-oxidizing Aubipyc complex, the gold(III) oxidation state is conserved, and a gold(III) fragment still containing the original ligand is found to be associated with the target proteins. It is notable that the C-terminal dodecapeptide of thioredoxin reductase containing the characteristic –Gly–Cys–Sec–Gly metal-binding motif is able in all cases to trigger gold(III)-to-gold(I) reduction. Our investigation allowed us to identify in detail the nature of the gold fragments that ultimately bind the protein targets and determine the exact binding stoichiometry; some insight on the reaction kinetics was also gained. Notably, a few clear correlations could be established between the structure of the metal complexes and the nature of the resulting protein adducts. The mechanistic implications of these findings are analyzed and thoroughly discussed. Overall, the present results set the stage to better understand the real target biomolecules of these gold compounds and elucidate at the atomic level their interaction modes with proteins and peptides.

Keywords: anticancer metal complexes, gold, protein interaction, mass spectrometry, cytotoxic compounds
INTRODUCTION

During the last two decades, a number of studies highlighted the importance of gold compounds as a new family of cytotoxic agents with the potential of becoming new effective anticancer drug candidates endowed with original mechanisms of action and a peculiar spectrum of antitumor activities (Nobili et al., 2010; Zou et al., 2015). Indeed, a variety of gold(III) and gold(I) compounds, bearing different structural motifs, were reported to cause extensive cell death in vitro in numerous cancer cell lines, with a remarkable selectivity for cancer over normal cells (Casini et al., 2009). From the mechanistic studies conducted so far, the modes of action and the targets of antiproliferative gold compounds appear to be multifaceted and deeply distinct from those of clinically established platinum compounds (i.e., cisplatin); yet the “true” molecular mechanisms of medicinal gold compounds remain largely unexplored (Fiskus et al., 2014). A growing body of evidence suggests that a few selected protein targets such as the enzyme thioredoxin reductase (Saclon et al., 2018) and some transcription factors with zinc finger motifs (Abbehausen, 2019) mediate primarily the biological effects of cytotoxic gold compounds. This prompted investigators to analyze in detail the reactions of medicinal gold compounds with proteins. A systematic investigation on the interactions of the reference gold(I) drug auranofin with a series of model proteins, i.e., human serum albumin, carbonic anhydrase, superoxide dismutase, and hemoglobin, was recently carried out in our laboratory through mass spectrometry, and the resulting adducts could be characterized in molecular detail (Pratesi et al., 2016, 2018, 2019; Magherini et al., 2018; Cirri et al., 2019; Zoppi et al., 2020). These studies revealed that auranofin targets quite selectively the free cysteine residues of proteins (Pratesi et al., 2018; Zoppi et al., 2020).

Here, we have extended this kind of investigation to four representative gold(III) compounds for which extensive biological and mechanistic data have been gathered in the last years, namely, Auoxo6, Au2-phen, AuL12, and Aubipyc (Marzano et al., 2011; Gabbiani et al., 2012a,b). More precisely, the remarkable antiproliferative effects of the structurally related Auoxo6 and Au2-phen complexes were highlighted since the late 2000s by our research group in connection with the group of Cinellu et al. (2010), Casini et al. (2006). The complex AuL12 was developed and characterized, in Padua, by the research group of Marzano et al. (2011); Aubipyc was prepared in Sassari by the research team of Marcon et al. (2002), and its biological profile was later analyzed in connection with our research group (Marzo et al., 2015; Massai et al., 2016a). Here, we have studied the reactions of the above-mentioned gold(III) compounds with two representative proteins, i.e., HSA and hCA I; in addition, we have decided to perform the same interaction studies against the C-terminal redox-active domain of thioredoxin reductase, an important enzyme involved in cellular redox homeostasis regulation that is the putative target for gold compounds. Our investigation mainly relies on MS determinations, but MS results are independently supported by other biophysical techniques such as 1H NMR and UV–Vis. Notably, the results of this multi-technique approach turned out to be nicely consistent each other and allowed us to identify for each of the four selected gold complexes the precise nature of the metallic fragments that bind the investigated biomolecules. Characteristic trends in the analyzed metallodrug/biomolecule reaction could be identified and correlated to the structural and chemical features of the study compounds.

THE PANEL OF GOLD(III) COMPLEXES AND THE INVESTIGATIVE STRATEGY

The chemical formulas of the study compounds are synoptically shown in Figure 1.

Auoxo6 and its analogous Au2-phen, with two 2,9-dimethyl phenanthrolines in the place of two bipyridines, are binuclear Au(III) coordination compounds with a dioxo-bridge, which links the two gold(III) centers. Their main feature is the presence of an extended, roughly planar system containing the Au2O2 diamond core and the two aromatic moieties. Crystal structures for these compounds were previously determined (Gabbiani et al., 2008; Cinellu et al., 2010). These two gold(III) compounds are strictly related to each other from the structural point of view but greatly differ in their aqueous solubility, with Auoxo6 being far more soluble than Au2-Phen. Notably, both these gold(III) compounds manifest a frank oxidizing character and tend to undergo facile reduction to gold(I) or, alternatively, to elemental gold. Their reactions with biologically reducing agents such as glutathione and ascorbate were earlier investigated, and quick gold(III) reduction was indeed documented (Gabbiani et al., 2012b). However, in the absence of reducing agents, these gold(III) complexes are stable under physiological conditions for several hours or even days and are thus well suitable for pharmaceutical application (Gabbiani et al., 2012b).

AuL12 is a mononuclear gold(III) complex developed in the group of Prof. Dolores Fregona, in Padua, that revealed very promising anticancer properties both in vitro and in vivo (Ronconi et al., 2012; Nardon and Fregona, 2015). AuL12 consists of a square-planar gold(III) center with a bidentate dithiocarbamate ligand and two bromide ligands. Notably, AuL12 was shown to behave as a prodrug upon releasing its bromide ligands (Pratesi et al., 2019). Significant oxidizing properties were also documented for this gold(III) complex (Nardon et al., 2017).

Aubipyc is a gold(III) cyclometalated derivative of 6-(1,1-dimethylbenzyl)-2,2′-bipyridine, where the tetracoordinated square planar gold(III) center is surrounded by the N,N,C sequence of donor atoms from the terdentate bipyridine ligand plus an oxygen atom from the hydroxo ligand (Cinellu et al., 1996). At variance with the above gold(III) complexes, the direct carbon-to-metal bond greatly stabilizes the gold(III) center in Aubipyc; a notable consequence is that Aubipyc is not reduced by glutathione (Gamberi et al., 2014).

Some years ago, the in vitro anticancer properties of these four gold(III) complexes were evaluated comparatively in a standard 36-cancer cell line panel available in Oncotest (Freiburg, Germany) (Casini et al., 2009). The COMPARE algorithm...
applied to the analysis of the obtained growth inhibition data revealed that the profiles of Au$_2$phen are very similar to those of Auoxo6, in agreement with their pronounced structural analogy (Cinellu et al., 2010). Tentatively, through bioinformatic analysis, the cytotoxicity patterns obtained for Au$_2$phen and Auoxo6 were mainly ascribed to inhibition of histone deacetylase. At variance, Aubipy was found to be only moderately effective in the Oncotest panel (Casini et al., 2009). Also, AuL12 was confirmed to be highly cytotoxic in the Oncotest panel, with a mode of action resembling antiproteasomal agents (Casini et al., 2009; Zhang et al., 2010). Interestingly, the correlations in the antiproliferative profiles between these gold compounds and cisplatin were very poor, implying again the occurrence of profoundly different modes of action. On the whole, COMPARE analysis of these gold compounds suggested that a variety of proteins might be reliable biomolecular targets and thus account for the observed biological effects; this means that the biological actions of these gold compounds are best interpreted in terms of metalation and inactivation of a few crucial proteins that are effective cancer targets (Cinellu et al., 2010).

The biological studies were later supported by a number of proteomic studies highlighting the alterations in protein expression induced by the above gold(III) complexes (Magherini et al., 2010; Guidi et al., 2012; Gamberi et al., 2014).

During the last decade, the interactions of some of these gold(III) compounds with model proteins were also investigated from the crystallographic point of view, mostly in the research group of Prof. Antonello Merlino in Naples. Those crystallographic studies clearly supported the occurrence of gold(III)-to-gold(I) reduction in the cases of Auoxo6, Au$_2$phen, and AuL12 reacting with proteins (Russo Krauss et al., 2014; Merlino et al., 2017; Ferraro et al., 2019; Giorgio and Merlino, 2020).

In the last few years, ESI MS has emerged as a powerful tool to monitor the interactions of metallodrugs with proteins at the molecular level (Merlino et al., 2017). These recent developments are described in a couple of review articles (Merlino et al., 2017;
Accordingly, we have exploited the ESI MS method to characterize in a systematic way and comparatively the interaction of the four study metallo-drugs with two exemplary proteins and with the C-terminal dodecapeptide of thioredoxin reductase.

Briefly, the adopted experimental strategy was as follows. All four gold complexes were challenged with HSA, hCA 1, and the TrxR dodecapeptide according to a well-established experimental protocol (Tamasi et al., 2014; Marzo et al., 2017, 2019; Michelucci et al., 2017; Pratesi et al., 2018; Ferraro et al., 2020; Zoppi et al., 2020). Different times and stoichiometries were explored to identify the best conditions to obtain adduct formation and to improve the quality of the ESI MS spectra. In addition, particular attention was paid to the kinetic aspects of these reactions.

Indeed, MS turned out to be a powerful tool to characterize the metallo-drug/protein adduct that formed in the course of the above reaction. Systematic MS measurements were able to define the general patterns of reactivity between gold compounds and the model proteins; however, in selected cases, UV–Vis and NMR spectroscopies were valuable ancillary techniques to better understand specific features of the investigated systems and of the resulting adducts.

**THE ELECTROSPRAY IONIZATION MASS SPECTROMETRY MEASUREMENTS**

The ESI MS measurements were performed according to the procedure developed in our laboratory, which is described in detail in the Materials and Methods (Tamasi et al., 2014; Massai et al., 2016b; Pratesi et al., 2016, 2018; Zoppi et al., 2020). Briefly, each protein sample, dissolved in ammonium acetate solution 2 × 10−3 M at pH 6.8, was incubated with each selected gold(III) complex for 2 or 24 h in a well-defined molar ratio; then the samples were analyzed by high-resolution ESI MS through direct infusion in the mass spectrometer upon addition of a small aliquot of formic acid. The obtained MS results are shown below for each gold complex/biomolecule pair.

Remarkably, all the selected biomolecules contain a free exposed cysteine or selenocysteine (in the case of the TrxR dodecapeptide) residue, as gold–sulfur/selenium interactions are strongly preferred according to the Pearson concept (Dabrowiak, 2012).

**The Reactions of Gold Compounds With Human Serum Albumin**

HSA is characterized by the presence of 17 disulfide bonds and only one free cysteine residue (Cys34) (Rombouts et al., 2015). Interestingly, the only free cysteine (Cys34) of HSA is solvent accessible and is considered the primary binding site for gold compounds owing to the high affinity of gold to sulfur-containing ligands (Pratesi et al., 2018, 2019; Zoppi et al., 2020).

The deconvoluted high-resolution mass spectrum of HSA is shown in Figure 2A. The main peak at 66,437 Da corresponds to the native protein and the second intense peak at 66,556 Da is assigned to a common HSA posttranslational modification, i.e., the cysteinylation form of the native protein (Fasano et al., 2005; Talib et al., 2006; Fanali et al., 2012).

Upon reacting HSA with either Auoxo6 or AuPhen, an apparent decrease in the overall quality of the ESI MS spectra is noticed, which is accompanied by a strong baseline distortion, with both tested stoichiometries (1:3 or 1:0.9 protein/metal ratio).

In our previous experience, this behavior is quite common when dealing with metal complexes where the metal center is present in its higher oxidation state; probably this arises from the occurrence of a direct redox reaction between the metal complex and the biomolecule, leading to a plethora of minor adducts that are present in small amounts and are difficult to assign (Massai et al., 2019; Pratesi et al., 2019).

In spite of that, the resulting spectra still allow the detection of a few metal–protein adducts with greater molecular masses that the native protein. The peaks corresponding to these adducts are annotated on the spectra shown in Figure 2. In the case of Auoxo6 and AuPhen (Figures 2B,C, respectively), the gold adducts are formed on the cysteinylated protein. These adducts are characterized by the probable presence of gold clusters, which in the case of the most reactive Auoxo6 (Figure 2B) complex consist of a maximum of 5 gold atoms, represented by the peak at 67,537 Da. Also in the case of AuPhen, the adducts are formed on the cysteinylated HSA, but due to the lower reactivity of AuPhen in comparison with Auoxo6, the gold clusters formed on the protein consist of a maximum of 2 gold atoms, with a total molecular mass of 66,951 Da (Figure 2C). A further confirmation of the presence of metallic gold clusters can be obtained from the inspection of the multicharged ESI spectra. In fact, the presence of a metal cluster, differently from the metal ions, does not bring any contribution to the overall charge of the adducts and does not affect the m/z ratio of the multicharged signals that is due in this case only to the protonation process inside the ESI source (Johnson et al., 2000; Johnson and Laskin, 2016; Chen et al., 2019).

Far better spectra are obtained upon reacting HSA with Aul2 (Figure 2D). Remarkably, the peak observed at 66,779 Da corresponds to a species where the Au(III) ethylsarcosine dithiocarbamate (ESDT) fragment is bound to the protein. Additional peaks at lower mass values are seen corresponding to the Au(I)/HSA adduct, implying that Aul2 may also undergo reduction to gold(I) with loss of the dithiocarbamate ligand, as already described in a previous work of ours concerning the reactivity of the bovine serum albumin (BSA) with AuL2 (Pratesi et al., 2019).

Contrariwise, the Aubipyc complex is far more stable from the redox point of view than the previously mentioned gold(III) compounds (Gabbiani et al., 2012b; Marzo et al., 2015; Kupiec et al., 2019). Usually, the reduction of the gold(III) center is not observed for this complex. It follows that upon reaction with Aubipyc, the spectrum of HSA is dominated by a peak at 66,906 Da corresponding to the native HSA bearing the Aubipyc moiety without the hydroxo group (Figure 2E). Another peak at 67,394 Da corresponds to the bis-adduct of HSA with the same molecular fragment. In contrast with the results described for the previous gold(III) compounds, in this case, the lack of adducts formed with cysteinylated HSA suggests that this modification...
FIGURE 2 | (A) Deconvoluted electrospray ionization quadrupole time-of-flight (ESI-Q-TOF) spectra of human serum albumin (HSA) $5 \times 10^{-7}$ M in 2 mM of ammonium acetate solution at pH 6.8 and incubated at $37^\circ$ C for 2 h with (B) Auoxo6, (C) Auphen, (D) AuL12, and (E) Aubipyc solution in dimethyl sulfoxide (DMSO) in a 1:0.9 protein-to-gold ratio; 0.1% v/v of formic acid was added just before infusion.
of the only free cysteine prevents the reaction with Aubipyc. This could be due to the greater stability of the \(-S-S-\) bond in the cysteinylated HSA with respect to the potential \(-S-Au(III)\) interaction with the Aubipyc reactive moiety. Thus, a clearly different behavior has been highlighted for the Aubipyc complex compared with Auoxo6 and Au2phen.

**The Reactions of Gold Compounds With Human Carbonic Anhydrase I**

On the whole, the ESI MS spectra obtained for hCA I and its adducts with the study gold compounds turned out to be of greater quality than those of HSA, possibly in relation to the greater ionizability of this protein and its lower size.

Human carbonic anhydrase I (hCA I) consists of 261 amino acids and contains a Zn(II) ion essential for catalysis. The enzyme presents a free cysteine (Cys213) as a potential anchoring site for gold.

The analysis of the ESI MS spectra is quite straightforward. Indeed, when reacting hCA I with the three gold(III) complexes endowed with a more oxidizing character, i.e., Auoxo6, Au2phen, and AuL12, adducts with an increasing number of Au atoms bound to apo-hCA I are again detected (Figure 3).

Regarding the complex AuL12, the recorded spectra show the formation of the mono- and bis-adduct with the Au atoms (Figure 3D).

Noteworthy, the ESI MS spectra of hCA I reacted with Auoxo6 or Au2Phen show many signals that are attributed to the binding to hCA I of a number of Au atoms in different stoichiometries: from 3 to 7 in the case of Auoxo6 (Figure 3B) and from 2 to 4 for Au2Phen (Figure 3C). Moreover, it is worth noting that in both spectra (Figures 3B,C), the signal of unreacted apo-hCA I (28,780 Da) is not observed any more, meaning that the reaction with the gold compounds is rapid and nearly quantitative.

Thus, in the cases of Auoxo6, Au2Phen, and AuL12, a gold(III)-to-gold(0) reduction reaction occurs accompanied by the release of all the original gold(III) ligands. Also in this case, an inspection of the multicharged ESI spectra has been carried out to confirm the presence of gold clusters. Again, Aubipyc reveals a different behavior with no evident reduction of the gold(III) center and retention of the terdentate ligand. Only one Aubipyc moiety is found bonded to hCA I in the main adduct detected at 29,248 Da (Figure 3E).

**The Reactions of Gold Compounds With the C-Terminal Dodecapeptide of TrxR1**

Finally, the four gold(III) complexes were challenged with the C-terminal dodecapeptide of TrxR bearing the \(-Cys-Sec-\) motif. This peptide has been adopted since a few years by our research group as a model peptide mimicking the TrxR1 reactive site (Pratesi et al., 2010, 2014).

This peptide is characterized by the presence of an intramolecular \(-S-Se-\) bridge that requires reduction to give the reactive form of the peptide. This reaction is achieved by adding 10 eq. of dithiothreitol (DTT) before the incubation with the various gold complexes (Pratesi et al., 2014). The presence of the reductant greatly facilitates the reaction between selenocysteine and cysteine with the gold complexes.

A general reaction pattern is identified also in this case being perfectly superimposable to that of the other considered proteins. In particular, upon reacting Au2phen, AuL12, and even Aubipyc with the dodecapeptide, the main adduct formed corresponds to the binding of a gold(I) ion to the peptide (Figure 4). In addition, other minor signals are also present, related to adducts with higher Au(I)/peptide ratios. Apparently, in the case of Auoxo6, no reaction is observed under the same experimental conditions.

Interestingly, in the case of this peptide, the gold compounds’ reactivity is quite similar to that observed with the proteins. The main difference is that, in this latter case, the complete reduction from Au(III) to Au(0) does not occur. This behavior could be certainly ascribed to the marked difference in the chemical environment of the whole protein compared with a peptide fragment; however, this aspect will be further investigated.

Since Auoxo6 is the only compound that shows no reactivity with the peptide after a short time of incubation (2 h), other experiments were conducted. Different concentration ratios between the three reagents (the peptide, Auoxo6, and the DTT) were tested, in order to find the one that allows the adduct formation in short times. The best ratio was found to be the 1:1:10 (peptide to gold to DTT) in which a certain reactivity of the gold compound is observed even at short times of incubation. Indeed, after 2 h, the signal at 1,398 Da attributed to the adduct of the peptide with Au(I) (and a NH2+ ion from the solution) is clearly observed (see Supplementary Figure 11), even if the signals of the peptide alone are still quite intense. After 24 h of incubation, no adduct signal is detected anymore.

**The Reactivity of Aubipyc in the Presence of a Reducing Agent**

The above-described experiments highlighted a different behavior of Aubipyc depending on the substrate considered. Indeed, upon reaction with HSA and hCA I, Aubipyc binds these proteins through the \([Au(III)(bipydmb-H)]\) environment of the whole protein compared with a peptide fragment; however, this aspect will be further investigated.

When performing the experiments with the peptide, a reducing agent, i.e., DTT, is needed to break the bond between the cysteine and selenocysteine residue and promote the binding of the metal. In order to assess if the reduction of the gold center in Aubipyc is due to DTT or, instead, to the biological environment of the whole protein binding the \([Au(III)(bipydmb-H)]\) fragment, with the gold center retaining the oxidation state +3; in contrast, upon reaction with the dodecapeptide, Aubipyc undergoes complete reduction and loss of the ligand so that an adduct containing a single Au(I) ion is formed.
FIGURE 3 | (A) Deconvoluted electrospray ionization quadrupole time-of-flight (ESI-Q-TOF) spectra of human carbonic anhydrase I (hCA I) $7 \times 10^{-7}$ M in 2 mM of ammonium acetate solution at pH 6.8 and incubated at 37$^\circ$C for 2 h with (B) Auoxo$_6$, (C) Au$_2$phen, (D) AuL$_{12}$, and (E) Auibypc solution in dimethyl sulfoxide (DMSO) in a 1:0.9 protein-to-gold ratio; 0.1% v/v of formic acid was added just before infusion.
FIGURE 4 | (A) Multicharged electrospray ionization quadrupole time-of-flight (ESI-Q-TOF) spectra of the dodecapeptide $5 \times 10^{-7}$ M in 2 mM of ammonium acetate solution at pH 6.8 and incubated at 37 °C for 2 h with (B) Auoxo6, (C) Au$_2$phen, (D) AuL$_12$, and (E) Aubipy solution in dimethyl sulfoxide (DMSO) in a 1:3:5 protein-to-gold-to-DTT ratio; 0.1% v/v of formic acid was added just before infusion.
retains the ligand and the oxidation state of +3. So it can be inferred that the reduction of the gold center to gold(I) in the case of the C-terminal dodecapeptide of TrxR is due to the nature of the substrate and not to the presence of DTT.

**COMPLEMENTARY BIOPHYSICAL MEASUREMENTS**

To gain more information about the interaction of the selected gold(III) complexes with the three targets, other experiments were carried out. More precisely, spectrophotometric and $^1$H NMR measurements were performed for achieving, if possible, independent confirmations of the results obtained through ESI MS measurements. In some cases, additional and valuable information was gained.

**Spectrophotometric Measurements**

In the case of Auoxo6, it was possible to elucidate a common redox-dependent binding process found for the interaction with all the three targets used in this investigation (Figure 5). More precisely, the time course spectra of samples offer a clear evidence of the occurrence of a gold(III) reduction mechanism, highlighted from the disappearance of the complex absorption bands located between 310 and 330 nm. Moreover, the reduction of Auoxo6 signals is accompanied by the growth of a new band located at 290 nm and assignable to the free 6,6′-dimethyl-2,2′-bipyridyl ligand. In the case of HSA and hCA I (Figures 5A,B), in addition, a new relevantly broad band appears in the visible region between 500 and 600 nm, usually diagnostic of the formation of elemental gold clusters (Domínguez-Medina et al., 2012; Tatini et al., 2014). Notably, all these results turned out to be in perfect agreement with those observed through the ESI MS experiments, in which HSA and hCA I show the binding with a polynuclear gold(0) cluster upon the interaction of Auoxo6, contrary to the case of thioredoxin reductase dodecapeptide model that was found to bind a naked gold(I) atom.

Also in the case of Au$_3$Phen, it was possible to gain a clear evidence of gold(0) formation at least in the case of the interaction with hCA I, confirming again the data collected through MS; on the other hand, Aubipyc, as already emerged from ESI MS measurements, does not seem to incur to any reduction process (see Supplementary Material for detailed spectra of these latter data: Supplementary Figures 7–10, 12, 13).

**$^1$H Nuclear Magnetic Resonance Measurements**

In order to confirm the reaction pattern observed in the ESI MS experiments, some NMR measurements were carried out. First of all, each investigated complex was incubated for 24 h with HSA. Subsequently, $^1$H NMR spectra were acquired through a Carr–Purcell–Meiboom–Gill pulse sequence used as a T2 filter for removing the HSA signals. Indeed, this experimental procedure is used for achieving the suppression of all resonances with short T2, typically belonging to high-molecular-weight molecules such as HSA or HSA/metal–complex adducts, allowing to record spectra not affected from broad signals that might hide small trace of complexes' degradation products (Pratesi et al., 2019). The NMR experiments turned out to be nicely in agreement with the ESI MS study.

More precisely:

(i) Upon incubation with HSA, AuL12 shows the same fragmentation pattern seen upon interaction with BSA (Pratesi et al., 2019). Indeed, also in this case, it is possible to identify two small molecules originated from AuL12 degradation mechanisms, i.e., ethanol (δ 3.64, 1.17) and ethyl sarcosinate (δ 4.30, 3.96, 2.79, 1.29) (see Supplementary Figure 5). This occurrence is in agreement with ESI MS data, in which only a gold/HSA adduct is visible in the spectrum, with a complete loss of the ligand from the metal center.

(ii) Contrary to the previous case, no Aubipyc signals were detected after incubation with HSA. The fact that all its resonances were completely suppressed from the T2 filter upon HSA interaction can easily be explained by assuming a coordination process on the protein scaffold in which the organic moiety of the metal complex was retained on the gold center. This latter occurrence was again in agreement with ESI MS experiments.

(iii) In the case of Auoxo6, signals imputable to 6,6′-dimethyl-2,2′-bipyridyl ligand were detected in solution as a consequence of the degradation of the complex (δ 8.71, 7.48, 7.43, one proton each; δ 3.34, three protons from the methyl group); see Figure 6. This latter result was again...
in perfect agreement with that obtained through ESI MS measurements, in which only a gold/HSA adduct was found. The case of the interaction of Au\textsubscript{2}phen with HSA turned out to be slightly more complicated. More precisely, the spectrum of the sample showed no signals, suggesting a behavior of Au\textsubscript{2}phen similar to that of Aubipy. On the other hand, this occurrence seems to be in contrast with ESI MS results, in which only the presence of the same gold/HSA adduct was detected as in the case of interactions with AuL\textsubscript{12} and Auoxo\textsubscript{6}. Anyway, this apparent contradiction can easily be explained, taking into account the precipitation of the ligand during the incubation process. Indeed, after the mixing of HSA and Au\textsubscript{2}phen, the formation of a precipitate occurs, most probably an adduct between HSA and the aromatic ligand lost from Au\textsubscript{2}phen. On the other hand, the formation of adducts between HSA and 1,10-phenanthroline systems was already reported in literature (Lin and Shen, 2017).

CONCLUSIONS—A GENERAL INTERPRETATION OF THE OBTAINED RESULTS

The above-reported results permit to identify some characteristic trends in the reactivity of the study gold(III) compounds with the tested protein targets. In particular, MS results provide a substantial body of comparative data on the various investigated systems. From the precise determination of the formed adducts, inferences may be drawn on the type of the occurring reactions in relation to the nature of the metal complex and of the interacting biomolecule.

From careful data analysis, some conclusions may be extracted, as follows:

The reactivity pattern first depends on the specific nature of the metal complex and its oxidizing character. Indeed, the more oxidizing gold(III) agents invariably tend to undergo reduction to gold(I) or gold(0); the reduction process is generally associated with complete metal complex degradation, with the exception of AuL\textsubscript{12}, which retains the dithiocarbamate ligand. Typically, the less-oxidizing Aubipy in its reaction with HSA and hCA I tends to conserve the gold center in the oxidation state +3 with complete retention of the terdentate ligand. Also, a not-negligible role is played by the nature of the protein. Indeed, the C-terminal dodecapeptide of thioredoxin reductase was found to be able to induce reduction even of the Aubipy complex to gold(I) with the loss of the ligand.

In conclusion, from these results, the prodrug character of these metal complexes is further documented. All of them are able to be a source of gold(I) ions that are capable of metalating proteins mostly at cysteine and selenocysteine.
residues. Production of gold(I) ions may be modulated through the oxidizing character of the complexes, especially for Auoxo6 and Au2phen, and the kinetics of the reduction reaction. Regarding Aubipyc, the different biomolecules promote the formation of different binding moieties; indeed, in the case of HSA and hCA I, the metal complex retains its oxidation state (+3), and the [Au(III)(bipy\textsubscript{dmb}-H\textsubscript{2})\textsuperscript{2+}] fragment binds the proteins, while in the presence of the dodecapeptide, a reduction of the gold center occurs, and the formation of Au(I)-peptide adduct is revealed.

Remarkably, in the presence of an excess of the gold complex, formation of small clusters containing 2–7 atoms of elemental gold is observed.

As indicated in several papers (Magherini et al., 2010; Cattaruzza et al., 2011; Huang et al., 2018; Altaf et al., 2019), the mechanisms of action of these gold(III) compounds seem to rely ultimately on protein metalation; moreover, the oxidizing character of the starting complex may play a role in the overall cytotoxic mechanism, further exacerbating the intracellular oxidative stress and reactive oxygen species (ROS) generation. The results of our work, highlighting the behavior of the gold(III) complexes in the presence of different biomolecules, seem to be an additional evidence to support the importance of redox mechanisms in the biological activity of these compounds.

MATERIALS AND METHODS

Materials
Lyophilized hCA I and HSA were purchased from Sigma-Aldrich and used without further purification or manipulation. Auoxo6, Au\textsubscript{2}phen, Aubipyc, and AuL12, as well as the dodecapeptide of thioredoxin reductase (dTrxR), were synthesized in the MetMed Laboratories at the Department of Chemistry, University of Florence, following already established procedures (Pratesi et al., 2010, 2014).

DTT and dimethyl sulfoxide (DMSO) were purchased from Fluka. Liquid chromatography (LC)–MS materials (water, methanol, and ammonium acetate) were purchased from Sigma-Aldrich. Deuterated solvents (D\textsubscript{2}O and DMSO-\textsubscript{d\textsubscript{6}}) were purchased from Sigma-Aldrich.

Electrospray Ionization Mass Spectrometry
Experimental Conditions
Sample Preparation
Stock solutions of hCA I 10\textsuperscript{-4} M, HSA 10\textsuperscript{-3} M, and dTrxR 10\textsuperscript{-3} M were prepared, dissolving the proteins and the peptide in H\textsubscript{2}O of LC-MS grade. Stock solutions 10\textsuperscript{-2} M of the gold(III) compounds were prepared by dissolving the samples in DMSO. Stock solution 10\textsuperscript{-1} M of DTT was prepared in H\textsubscript{2}O.

For the experiments with HSA, solutions of the protein 10\textsuperscript{-4} M and each gold compound at protein-to-metal ratios 1:0.9 or 1:3 were prepared by diluting with ammonium acetate solution 2 × 10\textsuperscript{-3} M, pH 6.8. The mixtures were then incubated at 37 °C up to 24 h.

For Aubipyc, another sample was prepared, as follows: a solution 10\textsuperscript{-3} M of the protein was prepared by diluting with ammonium acetate solution 2 × 10\textsuperscript{-3} M, pH 6.8. Then an aliquot of DTT stock solution was added in a protein/reducing agent 1:5 ratio; then the mixture was incubated at 37 °C up to 30 min. After that time, an aliquot of Aubipyc was added in a protein-to-metal compound ratio of 1:0.9. The mixture thus obtained was incubated at 37 °C up to 24 h.

For the experiments with hCA I, solutions of the protein 10\textsuperscript{-5} M and each gold compound at protein-to-metal ratio 1:3 were prepared by diluting with ammonium acetate solution 2 × 10\textsuperscript{-3} M, pH 6.8. The mixtures were then incubated at 37 °C up to 24 h.

For the experiments with TrxR peptide, solutions of the peptide 10\textsuperscript{-4} M were prepared by diluting with ammonium acetate solution 2 × 10\textsuperscript{-3} M, pH 6.8. Then aliquots of DTT stock solution were added in a peptide to reducing agent ratios (1:5, 1:10); then the mixtures were incubated at 37 °C up to 30 min. After that time, aliquots of the gold(III) compounds’ solutions were added in peptide-to-metal compound ratios 1:1 or 1:3. The mixtures thus obtained were incubated at 37 °C up to 24 h.

Electrospray Ionization Mass Spectrometry Analysis: Final Dilutions
After the incubation time, all solutions were sampled and diluted to a final protein concentration of 7 × 10\textsuperscript{-7} M for hCA I, 5 × 10\textsuperscript{-7} M for HSA, and dTrxR using ammonium acetate solution 2 × 10\textsuperscript{-3} M, pH 6.8.

The HSA and hCA I final solutions were also added with 0.1% v/v of formic acid just before the infusion in the mass spectrometer.

Instrumental Parameters
The ESI mass study was performed using a TripleTOF® 5600+ high-resolution mass spectrometer (Sciex, Framingham, MA, United States), equipped with a DuoSpray® interface operating with an ESI probe. Respective ESI MS spectra were acquired through direct infusion at 5 µl/min of flow rate.

The general ESI source parameters optimized for each protein and peptide analysis were as follows:

HSA: positive polarity, ion spray voltage floating 5,500 V, temperature 0, ion source Gas 1 (GS1) 45 L/min; ion source Gas 2 (GS2) 0; curtain gas (CUR) 12 L/min, collision energy (CE) 10 V; declustering potential (DP) 150 V, range 1,000–2,600 m/z.

hCA I: positive polarity, ion spray voltage floating 5,500 V, temperature 0, ion source Gas 1 (GS1) 40 L/min; ion source Gas 2 (GS2) 0; CUR 10 L/min, CE 10 V; DP 50 V, range 760–990 m/z.

dTrxR: positive polarity, ion spray voltage floating 5,500 V, temperature 0, ion source Gas 1 (GS1) 25 L/min; ion source Gas 2 (GS2) 25 L/min; CUR 30 L/min, CE 10 V; DP 50 V, range 1,000–2,000 m/z.

For acquisition, Analyst TF software 1.7.1 (Sciex) was used, and deconvoluted spectra were obtained by using the Bio Tool Kit micro-application v.2.2 embedded in PeakView™ software v.2.2 (Sciex).

Nuclear Magnetic Resonance
Samples were prepared as an HSA solution in D\textsubscript{2}O in which DMSO-\textsubscript{d\textsubscript{6}} stock solutions of the investigated compounds were added. The final concentrations were 2 mM of HSA with 1
equivalent of gold compound in D$_2$O/DMSO-d$_6$ 9:1. Samples were then incubated for 24 h at 37 °C before acquisition.

Acquisitions were performed using cpgm1dpr Bruker pulse sequence (monodimensional Carr–Purcell–Meiboom–Gill sequence with solvent presaturation). Offset frequency was set up to 4.79 ppm for achieving residual H$_2$O suppression, while echo time was set up to 6 ms and the echo loop repeated for 126 times before free induction decay (FID) acquisition (1.512 s of total delay).

**UV–Visible Spectrophotometric Studies**

The electronic spectra were recorded by diluting small amounts of freshly prepared concentrated solutions of HSA, hCA I, or dodecapeptide, in the reference solution (2 mM of ammonium acetate, pH 6.8), at final protein/peptide concentration of 10$^{-5}$ M. Each gold complex has been added, after the recording of the protein/peptide baseline, at a stoichiometric ratio of 3:1 (metal to protein). The resulting solutions were monitored by collecting the electronic spectra over 24 h at 37 °C.

**DATA AVAILABILITY STATEMENT**

All datasets generated for this study are included in the article/Supplementary Material.

**AUTHOR CONTRIBUTIONS**

AP, LMa, and LMe designed, coordinated, and supervised the whole study. DC carried out the NMR experiments. CZ and LMa acquired all the ESI MS and UV–Vis spectra. AP, DC, and LMe wrote the manuscript. All authors revised the experimental part and the discussion and approved the final version of the manuscript. All authors contributed to the article and approved the submitted version.

**FUNDING**

AP gratefully acknowledges the Beneficentia Stiftung, Vaduz (BEN2020/34) and University of Pisa (Rating Ateneo 2019–2020) for the financial support. DC gratefully acknowledges Associazione Italiana per la Ricerca sul Cancro for the financial support (AIRC 2-year Fellowship for Italy, Project Code: 23852). LMe, LMa, and AP acknowledge the Fondazione Italiana per la Ricerca sul Cancro (AIRC), Milan, and Fondazione Cassa Risparmio Firenze for funding the project Advanced mass spectrometry tools for cancer research: novel applications in proteomics, metabolomics, and nanomedicine (Multiuser Equipment Program 2016, ref. code 19650).

**ACKNOWLEDGMENTS**

All authors acknowledge the CIRCMSB (Consorzio Interuniveristario di Ricerca in Chimica dei Metalli nei Sistemi Biologici) for the fruitful and constructive scientific discussion.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2020.581648/full#supplementary-material

**REFERENCES**

Abbehausen, C. (2019). Zinc finger domains as therapeutic targets for metal-based compounds—an update. *Metalomics* 11, 15–28. doi: 10.1039/C8MT00262B

Altaf, M., Casagrande, N., Mariotto, E., Baig, N., Kawde, A. N., Corona, G., et al. (2019). Potent *in vitro* and *in vivo* anticancer activity of new bipyridine and bipyrimidine gold (III) dithiocarbamate derivatives. *Cancers* 11:474. doi: 10.3390/cancers11040474

Casini, A., Cinellu, M. A., Minghetti, G., Gabbiani, C., Coronello, M., Mini, E., et al. (2006). Structural and solution chemistry, antiproliferative effects, and DNA and protein binding properties of a series of dinuclear gold(III) compounds with bipyridyl ligands. *J. Med. Chem.* 49, 5524–5531. doi: 10.1021/jm060436a

Casini, A., Kelter, G., Gabbiani, C., Cinellu, M. A., Minghetti, G., Fregona, D., et al. (2009). Chemistry, antiproliferative properties, tumor selectivity, and molecular mechanisms of novel gold(III) compounds for cancer treatment: a systematic study. *J. Biol. Inorg. Chem.* 14, 1139–1149. doi: 10.1007/s00775-009-0558-9

Cattaruzza, L., Fregoni, D., Mongiat, M., Ronconi, L., Fassina, A., Colombatti, A., et al. (2011). Antitumor activity of gold(III)-dithiocarbamate derivatives on prostate cancer cells and xenografts. *Int. J. Cancer* 128, 206–215. doi: 10.1002/ijc.25311

Chen, T., Yao, Q., Nasaruddin, R. R., and Xie, J. (2019). Electrospray ionization mass spectrometry: a powerful platform for noble metal nanocluster analysis. *Angew. Chem. Int. Ed.* 58, 11967–11976. doi: 10.1002/anie.201901970

Cinellu, M. A., Maiore, L., Manassero, M., Casini, A., Arca, M., Fiebig, H. H., et al. (2010). [Au2(phen2Me)2(µ-O2)] (PF6)2, a novel dinuclear gold(III) complex showing excellent antiproliferative properties. *ACS Med. Chem. Lett.* 1, 336–339. doi: 10.1021/ml100097f

Cinello, M. A., Zucca, A., Stoccoro, S., Minghetti, G., Manassero, M., and Sansoni, M. (1996). Synthesis and characterization of gold(III) adducts and cyclometallated derivatives with 6-benzyl- and 6-alkyl-2,2′-bipyridines. *J. Chem. Soc. Dalton Trans.* 1996, 4217–4225. doi: 10.1039/DT960004217

Cirri, D., Fabbbrini, M. G., Massai, L., Pillozi, S., Guerri, A., Menconi, A., et al. (2019). Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin. *BioMetals* 32, 939–948. doi: 10.1007/s10534-019-00924-1

Dabrowiak, J. C. (2012). Metals in medicine. *Inorg. Chim. Acta* 393, 1–2. doi: 10.1016/j.ica.2012.07.022

Dominguez-Medina, S., McDonough, S., Swanglap, P., F., Landes, C., and Link, S. (2012). *In situ* measurement of bovine serum albumin interaction with gold nanoparticles. *Langmuir* 28, 9311–9319. doi: 10.1021/la3005213

Fanali, G., Di Masi, A., Trezza, V., Marino, M., Fasano, M., and Ascenzi, P. (2012). Human serum albumin: from bench to bedside. *Mol. Aspects Med.* 33, 209–290. doi: 10.1016/j.mam.2011.12.002

Fasano, M., Curry, S., Terreno, E., Galliano, M., Fanali, G., Narciso, P., et al. (2005). The extraordinary ligand binding properties of human serum albumin. *IUBMB Life* 57, 787–796. doi: 10.1515/IUBMB.57.9.0787

Ferraro, G., Giorgio, A., Mansour, A. M., and Merlino, A. (2019). Protein-mediated disproportionation of Au(I): insights from the structures of adducts of Au(III) compounds bearing N- pyridylbenzimidazole derivatives with lysozyme. *Dalton Trans.* 48, 14027–14035. doi: 10.1039/C9DT02729G

Ferraro, G., Pratesi, A., Messori, L., and Merlino, A. (2020). Protein interactions of dirhodium tetracetate: a structural study. *Dalton Trans.* 49, 2412–2416. doi: 10.1039/C9DT04819G

All authors acknowledge the CIRCMSB (Consorzio Interuniveristario di Ricerca in Chimica dei Metalli nei Sistemi Biologici) for the fruitful and constructive scientific discussion.

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fchem.2020.581648/full#supplementary-material
Fiskus, W., Saba, N., Shen, M., Ghias, M., Liu, J., Gupta, S., et al. (2014). Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. *Cancer Res. 74*, 2520–2532. doi: 10.1158/0008-5472.CAN-13-2033

Gabbiani, C., Casini, A., Messori, L., Guerri, A., Cinellu, M. A., Minghetti, G., et al. (2008). Structural characterization, solution studies, and DFT calculations on a series of binuclear gold(III) oxo complexes: relationships to biological properties. *Inorg. Chem. 47*, 2368–2379. doi: 10.1021/ic701254s

Gabbiani, C., Cinellu, M. A., Maioresi, L., Massai, L., Scaletti, F., and Messori, L. (2012a). Chemistry and biology of three representative gold(III) compounds as prospective anticancer agents. *Inorg. Chim. Acta 393*, 115–124. doi: 10.1016/j.jica.2012.07.016

Gabbiani, C., Massai, L., Scaletti, F., Michelucci, E., Maioresi, L., Cinellu, M. A., et al. (2012b). Protein metalation by metal-based drugs: reactions of cytoxic gold complexes with cytochrome c and lysozyme. *J. Biol. Inorg. Chem. 17*, 1293–1302. doi: 10.1007/s00775-012-0952-6

Gamberi, T., Massai, L., Magherini, F., Landini, I., Fiaschi, T., Scaletti, F., et al. (2014). Proteomic analysis of A2780/S ovarian cancer cell response to the cytoxic organogold(III) compound alipyc. *J. Proteomics 103*, 103–120. doi: 10.1016/j.jprot.2014.03.032

Giorgio, A., and Merlino, A. (2020). Gold metalation of proteins: structural studies. *Coord. Chem. Rev. 407*:213175. doi: 10.1016/j.ccr.2019.213175

Guidi, F., Puglia, M., Gabbiani, C., Landini, I., Gamberi, T., Fregona, D., et al. (2012). 2D-DIGE analysis of ovarian cancer cell responses to cytoxic gold compounds. *Mol. BioSyst. 8*, 985–993. doi: 10.1039/C1MB05386H

Huang, K.-B., Wang, F.-Y., Tang, X.-M., Feng, H.-W., Chen, Z.-F., Liu, Y.-C., et al. (2018). Organovalnetic gold(III) complexes similar to tetrahydroisoquinoline complexes with proven antitumor properties. *Eur. J. Inorg. Chem. 2017*, 1737–1744. doi: 10.1002/ejc.201601215

Nardon, C., and Fregona, D. (2015). Gold(III) complexes in the oncological preclinical arena: from aminoderivatives to peptidomimetics. *Curr. Topics Med. Chem. 16*, 360–380. doi: 10.2174/1568026615666150827094500

Nobili, S., Mini, E., Landini, I., Gabbiani, C., Cinellu, M. A., and Messori, L. (2010). Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies. *Med. Res. Rev. 30*, 550–580. doi: 10.1002/med.20168

Pratesi, A., Cirri, D., Pratesi, A., Gabbiani, C., Massai, L., Pettenozzo, N., Fusini, A., et al. (2017). Cell and cell-free mechanistic studies on two gold(III) complexes: relationships to biological properties. *J. Proteomics 58*, 905–911. doi: 10.1016/j.ijorb.2015.04.001

Pratesi, A., Cirri, D., Ciolfi, L., and Messori, L. (2018). Reactions of auranofin and its pseudohalide derivatives with serum albumin investigated through ESI-Q-TOF MS. *Inorg. Chem. 57*, 10507–10510. doi: 10.1021/acs.inorgchem.8b02177

Pratesi, A., Cirri, D., Fregona, D., Ferraro, G., Giorgio, A., Merlino, A., et al. (2019). Structural characterization of a gold/serum albumin complex. *Inorg. Chem. 58*, 10616–10619. doi: 10.1021/acs.inorgchem.9b01900

Pratesi, A., Gabbiani, C., Cinellu, M., and Messori, L. (2010). Reactions of medicinally relevant gold compounds with the C-terminal motif of thioredoxin reductase elucidated by MS analysis. *Chem. Commun. 46*, 7001–7003. doi: 10.1039/C6CC01465f

Pratesi, A., Gabbiani, C., Michelucci, E., Cinellu, M. A., Papini, A. M., Rubbiani, R., et al. (2014). Insights on the mechanism of thioredoxin reductase inhibition by Gold N-heterocyclic carbene compounds using the synthetic linear selenocysteine containing C-terminal peptide hTrXR(488-499): an ESI-MS investigation. *J. Inorg. Biochem. 136*, 161–169. doi: 10.1016/j.jinorgbio.2014.01.009

Romboius, I., Lagrain, B., Scherf, K. A., Koehler, P., and Delcour, J. A. (2015). Formation and resulfidation of disulfide bonds in bovine serum albumin demonstrated using tandem mass spectrometry with collision-induced and electron-transfer dissociation. *Sci. Rep. 5*:12210. doi: 10.1038/srep15589

Ronconi, L., Aldinucci, D., Ping Dou, Q., and Fregona, D. (2012). Latest insights into the anticancer activity of gold(III)-dithiocarbamate complexes. *Anti Cancer Agents Med. Chem. 10*, 283–292. doi: 10.2174/18715201079162292

Russo Krauss, I., Messori, L., Cinellu, M. A., Marasco, D., Sirignano, R., and Merlino, A. (2014). Interactions of gold-based drugs with proteins: the structure and stability of the adduct formed in the reaction between lysozyme and the cytoxic gold(III) compound Aurox3. *Dalton Trans. 43*, 17483–17488. doi: 10.1039/C4DT02332C

Scalcon, V., Bindoli, A., and Rigobello, M. P. (2018). Significance of the mitochondrial thioredoxin reductase in cancer cells: an update.
on role, targets and inhibitors. *Free Rad. Biol. Med.* 127, 62–79. doi: 10.1016/j.freeradbiomed.2018.03.043

Talib, J., Beck, J. L., and Ralph, S. F. (2006). A mass spectrometric investigation of the binding of gold antiarthritic agents and the metabolite [Au(CN)2]– to human serum albumin. *J. Biol. Inorg. Chem.* 11, 559–570. doi: 10.1007/s00775-006-0103-z

Tamasi, G., Carpini, A., Valensin, D., Messori, L., Pratesi, A., Scaletti, F., et al. (2014). [Ru(CO)x]-core complexes with selected azoles: synthesis, X-ray structure, spectroscopy, DFT analysis and evaluation of cytotoxic activity against human cancer cells. *Polyhedron* 81, 227–237. doi: 10.1016/j.poly.2014.05.067

Tatini, F., Landini, I., Scaletti, F., Massai, L., Centi, S., Ratto, F., et al. (2014). Size dependent biological profiles of PEGylated gold nanorods. *J. Mater. Chem. B* 2, 6072–6080. doi: 10.1039/C4TB00991F

Zhang, X., Frezza, M., Milacic, V., Ronconi, L., Fan, Y., Bi, C., et al. (2010). Inhibition of tumor proteasome activity by gold-dithiocarbamato complexes via both redox-dependent and -independent processes. *J. Cell. Biochem.* 109, 162–172. doi: 10.1002/jcb.22394

Zoppi, C., Messori, L., and Pratesi, A. (2020). ESI MS studies highlight the selective interaction of auranofin with protein free thiols. *Dalton Trans.* 49, 5906–5913. doi: 10.1039/D0DT00283F

Zou, T., Lum, C. T., Lok, C. N., Zhang, J. J., and Che, C. M. (2015). Chemical biology of anticancer gold(III) and gold(I) complexes. *Chem. Soc. Rev.* 44, 8786–8801. doi: 10.1039/C5CS00132C

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Massai, Zoppi, Cirri, Pratesi and Messori. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.